Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.58 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 8/20 | 0.55 |
| ▸ | FYN | P06241 | 6/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416288 | 0.89 | MET (0.49) | DYRK1ADYRK1BJAK2RETKDR | |
| SCHEMBL26176238 | 0.80 | PRKCI (0.47) | DYRK1ADYRK1BJAK2RETKDR | |
| SCHEMBL16562531 | 0.79 | DYRK1A (0.48) | DYRK1ADYRK1BJAK2RETKDR | |
| SCHEMBL16554646 | 0.78 | DYRK1A (0.50) | DYRK1ADYRK1BJAK2RETKDR | |
| SCHEMBL26174629 | 0.78 | ROCK2 (0.50) | DYRK1AMETAURKAROCK1LRRK2 | |
| SCHEMBL26175345 | 0.77 | PDPK1 (0.56) | ALK | |
| SCHEMBL25197327 | 0.76 | LRRK2 (0.47) | METROCK1LRRK2MAPK1 | |
| SCHEMBL30348542 | 0.76 | LRRK2 (0.47) | METROCK1LRRK2MAPK1 | |
| SCHEMBL19338499 | 0.76 | FYN (0.48) | DYRK1ADYRK1BMETFYNABL1 | |
| SCHEMBL360789 | 0.75 | DYRK1A (0.77) | DYRK1ADYRK1BJAK2RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | DYRK1A 560/4885DYRK1B 410/4885JAK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.